查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999327

骶髂关节融合市场：2026-2032年全球市场预测（依产品类型、手术方法、入路、固定机制、销售管道及最终用户划分）

Sacroiliac Joint Fusion Market by Product Type, Procedure Type, Approach, Fixation Mechanism, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，骶髂关节融合市场价值将达到 8.4842 亿美元，到 2026 年将成长至 9.4286 亿美元，到 2032 年将达到 19.1034 亿美元，年复合成长率为 12.29%。

主要市场统计数据
基准年 2025 8.4842亿美元
预计年份：2026年 9.4286亿美元
预测年份：2032年 1,910,340,000 美元
复合年增长率 (%) 12.29%

在不断发展的医疗环境中，骶髂关节融合手术的现状和临床需求影响着器械的开发、患者的治疗途径以及医疗保健提供者的决策。

随着临床医生寻求持久且微创的解决方案来治疗顽固性骶髂关节功能障碍，骶髂关节融合术在脊椎和骨盆治疗中占据越来越重要的地位。随着先进影像技术、标靶注射和多学科评估融入诊断流程，患者选择标准变得更加严格，明确了手术指征。同时，医疗设备研发人员和临床医生致力于降低组织创伤，提高动态稳定性，同时兼顾邻近解剖结构和长期融合的生物机制。

新技术和变革性护理模式正在迅速改变骶髂关节融合手术的技术、设备设计和临床实施模式。

骶髂关节融合术正经历一场变革，主要得益于植入材料、术中导航和手术物流的创新。影像和导航技术的进步降低了许多医疗团队对透视的依赖，从而缩短了学习曲线，并提高了手术室运作。导航辅助的微创技术能够实现更精准的植入，可望降低併发症发生率，并使更多患者能够接受手术。同时，植入形态和表面技术的改进，以及更丰富的材料选择，促使设计者致力于优化初始固定和长期融合的生物学特性。

评估 2025 年美国关税变化将如何影响所有利害关係人的供应链、采购重点、定价策略和业务永续营运。

2025年实施的一系列关税调整为医疗设备相关人员的采购和供应链策略引入了新的变数。从海外采购零件和成品的製造商正在重新评估其供应商所在地，以降低进口关税风险，这加速了关于近岸外包和双重采购的讨论。这些调整正在影响前置作业时间和库存策略，促使医院、门诊手术中心和专科诊所评估缓衝策略和合约柔软性，以维持医疗服务的连续性。

以细分市场为中心的分析揭示了每种产品类型、治疗方法、最终用户、途径、固定机制和销售管道的不同需求征兆。

以细分市场为重点的分析揭示了产品、手术流程、最终用户、手术入路、固定机制和销售管道等不同维度上的需求模式和发展重点。按产品类型划分，此细分市场区分植入和手术器械，尤其关注植入的材料选择。在植入，PEEK笼式结构与钛笼式结构展开竞争，两者在放射学和动态方面各有优势，影响着外科医师的选择。依手术类型划分，手术方式多种多样，涵盖微创手术到开放性手术。微创手术的特点在于采用透视引导流程和导航支援平台，而开放性手术则通常依赖手术技巧和既定的手术暴露策略。

影响全球采用率、报销管道、临床基础设施和商业化策略的区域趋势和患者人口统计。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的采纳选择、监管重点和商业化管道均有显着影响。在美洲，成熟的临床路径和高密度的先进脊椎中心促进了微创技术和先进植入的快速普及。同时，医院网路结构和门诊手术中心的成长也影响采购週期和采购谈判。在欧洲和中东及非洲，法规结构和报销体系的多样性导致采纳时间存在差异。一些市场优先考虑集中采购和成本效益分析，而另一些市场则优先考虑透过私人医院系统快速获取新型医疗设备。

对医疗设备製造商和服务供应商的竞争格局进行分析，重点在于策略倡议、产品创新、伙伴关係关係、市场进入方式以及能力差距。

骶髂关节融合领域企业的策略主要围绕着三大主题：差异化的临床价值、一体化服务交付和可扩展性。一些企业强调强大的临床证据和明确的手术优势，并将研发重点放在优化植入设计和手术器械的人体工学上，以缩短手术时间和降低併发症风险。同时，其他企业则致力于开发整合系统，将导航、植入和服务合约捆绑在一起，以降低手术团队和医疗机构采用该系统的门槛。医疗设备开发商与影像导航技术提供者之间的策略合作正逐渐成为建构贯穿整个手术流程（而不仅仅是单一产品）的统一解决方案的有效途径。

为帮助产业领导者加强产品组合、优化营运、加速产品推广以及应对政策和供应链逆风提供切实可行的策略建议。

产业领导者应推动一系列合作倡议，以平衡临床差异化、供应链韧性和市场进入的有效性。首先，应优先投资于高品质的对比临床证据和註册登记，使其符合支付方要求和外科医生决策标准，从而更清晰地展现手术对不同患者群体的益处。同时，应优化植入产品组合，重点关注模组化和互通性，以降低医院和门诊手术中心的库存管理复杂性，并加速采用新型材料和固定方式。

透明的调查方法透过明确说明资料来源、访谈架构、分析方法、检验通讯协定和局限性，确保整合可靠的证据。

本研究途径系统性地整合了同侪审查的临床文献、监管文件、操作指南和相关人员访谈，以建立可靠的证据基础。主要资料收集包括对不同临床环境下的临床医生、供应链和采购经理以及医疗设备商业化专家的访谈，以了解真实临床实践中的操作考虑和应用驱动因素。次要研究则纳入了医疗设备附加檔说明书、临床实验室註册资料和技术白皮书，以检验临床性能属性和器械特性。

简洁的结论整合了临床、商业性和政策影响，并概述了相关人员将见解转化为策略行动的优先事项。

总而言之，骶髂关节融合术正处于转折点，医疗设备创新、手术流程改善和供应链趋势的共同作用正在重塑临床实践和商业策略。在临床方面，影像和导航技术的进步，以及材料和固定方法的创新，正在扩大微创手术的安全范围，同时，在适当情况下，开放性手术仍然是一种选择。在商业方面，需要製定周密的市场进入计划，使产品设计与医院、门诊手术中心和专科诊所的营运实际情况相符，从而应对产品类型、手术流程、医疗机构环境、手术入路、固定机制和销售管道等多方面的市场细分。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 销售管道分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：骶髂关节融合市场：依产品类型划分

  • 植入
    • PEEK笼
    • 钛笼
  • 装置

第九章：骶髂关节融合术市场：依手术方法划分

  • 微创
    • 在透视下
    • 导航支援
  • 开放性手术

第十章：骶髂关节融合市场：依手术方式划分

  • 侧
  • 落后
  • 后外侧

第十一章：骶髂关节融合市场：以固定机制划分

  • 椎间融合装置
  • 板式固定
  • 桿固定
  • 螺丝固定

第十二章：骶髂关节融合市场：依销售管道划分

  • 直销
  • 销售代理

第十三章：骶髂关节融合市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十四章 骶髂关节融合市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：骶髂关节融合市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 骶髂关节融合市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国骶髂关节融合市场

第十八章：中国骶髂关节融合手术市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alphatec Spine, Inc.
  • Aurora Spine Corporation
  • Camber Spine Technologies, LLC
  • Captiva Spine, Inc.
  • CoreLink, LLC
  • DePuy Synthes, Inc.
  • Foundation Fusion Solutions, LLC
  • Genesys Orthopedic Systems, LLC
  • Globus Medical, Inc.
  • Life Spine, Inc.
  • Medtronic plc
  • NuVasive, Inc.
  • Orthofix Medical Inc.
  • PainTEQ, LLC
  • RTI Surgical, Inc.
  • SeaSpine Holdings Corporation
  • SI-BONE, Inc.
  • SIGNUS Medizintechnik GmbH
  • Stryker Corporation
  • VGI Medical, LLC
  • Xtant Medical Holdings, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-3A2E844FDC50

The Sacroiliac Joint Fusion Market was valued at USD 848.42 million in 2025 and is projected to grow to USD 942.86 million in 2026, with a CAGR of 12.29%, reaching USD 1,910.34 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 848.42 million
Estimated Year [2026] USD 942.86 million
Forecast Year [2032] USD 1,910.34 million
CAGR (%) 12.29%

Sacroiliac joint fusion landscape and clinical imperatives shaping device development patient pathways and provider decision-making in an evolving care environment

Sacroiliac joint fusion occupies an increasingly prominent place within the spine and pelvic care continuum as clinicians seek durable, minimally disruptive solutions for patients with refractory sacroiliac joint dysfunction. Patient selection has sharpened as diagnostic pathways integrate advanced imaging, targeted injections, and multidisciplinary evaluation, resulting in clearer indications for procedural intervention. Concurrently, device developers and proceduralists have focused on reducing tissue disruption and improving biomechanical stability while accounting for adjacent anatomy and long-term fusion biology.

This introduction frames the clinical landscape in which implants, instruments, procedural approaches, and facility types interact. Minimally invasive pathways are gaining traction alongside established open techniques, and approaches such as lateral and posterior access each offer distinct risk-benefit profiles that inform surgeon preference and device design. Meanwhile, differentiation between implant materials and fixation mechanisms reflects a balance of biomechanical performance, imaging compatibility, and surgeon familiarity. As hospitals, ambulatory surgical centers, and specialty clinics adapt to evolving reimbursement and care delivery models, decision-makers will increasingly evaluate devices not only on clinical outcomes but on integration into existing workflows, instrument sterilization practices, and inventory strategies.

Taken together, advancements in imaging guidance and navigation, coupled with iterative implant design, set the stage for continued refinement of patient pathways and adoption dynamics in the sacroiliac fusion arena.

Emerging technologies and care model disruptions driving rapid shifts in sacroiliac joint fusion procedures device design and clinical adoption patterns

The sacroiliac fusion landscape is undergoing transformative shifts driven by innovation in implant materials, intraoperative guidance, and procedural logistics. Advances in imaging and navigation have reduced dependence on fluoroscopic exposure for many teams, which in turn influences the procedural learning curve and operating room throughput. Navigation-assisted minimally invasive techniques enable more precise implant placement, potentially lowering complication rates and broadening the pool of patients eligible for intervention. At the same time, improvements in implant geometry and surface technology-coupled with expanded material choices-have encouraged designers to optimize for both initial fixation and long-term fusion biology.

Operationally, ambulatory surgical centers have embraced simplified instrumentation and streamlined procedural sets to support high-volume, low-cost delivery of care, while hospitals maintain a focus on complex cases and post-acute pathways. Distribution models have adapted accordingly: direct relationships between manufacturers and high-volume systems accelerate customization and service integration, whereas distributor-led channels remain critical for broad geographic reach and smaller facilities. Regulatory clarity and payer engagement around procedural coding and evidence requirements are also shaping product development priorities, incentivizing higher-quality clinical data and registry participation. Collectively, these shifts are recalibrating competitive dynamics and creating opportunities for entrants that can demonstrate clear value propositions across clinical outcomes, workflow efficiency, and total cost of care.

Assessment of how United States tariff changes in 2025 are reshaping supply chains procurement priorities pricing strategies and operational resilience across stakeholders

The suite of tariff changes enacted in the United States in 2025 has introduced new variables into procurement and supply chain strategies for medical device stakeholders. Manufacturers that source components or finished goods internationally have revisited supplier footprints to mitigate inbound duty exposure, accelerating conversations around nearshoring and dual-sourcing. These adjustments have implications for lead times and inventory policies, prompting hospitals, ambulatory surgical centers, and specialty clinics to evaluate buffer strategies and contractual flexibility to maintain continuity of care.

Procurement teams have increased scrutiny on landed cost calculations and total procurement cycle time, which has shifted negotiation dynamics with both direct manufacturers and distributors. For some suppliers, the tariff environment has catalyzed investments in domestic manufacturing capacity or in tariff engineering approaches to reclassify value-added processes, while others have absorbed duties to preserve competitive pricing and maintain market access. In practice, these strategic responses affect capital planning for facilities and can influence device selection where comparable clinical outcomes exist.

Importantly, policy uncertainty associated with tariff implementation timelines has elevated the strategic value of adaptive sourcing and scenario planning. Stakeholders that foster transparency across the supply chain and prioritize contractual resilience are positioning themselves to maintain stable access to critical implants, instruments, and procedural consumables despite evolving trade policy frameworks.

Segment-focused analysis revealing differentiated demand signals across product types procedure modalities end users approaches fixation mechanisms and distribution channels

A segmentation-focused lens reveals differentiated demand patterns and development priorities across product, procedure, end user, approach, fixation mechanism, and distribution dimensions. Based on product type, the field separates implants from instruments, with implants drawing particular attention to material choice; within implants, PEEK cage designs compete against titanium cage constructs, each offering distinct radiographic and biomechanical considerations that influence surgeon preference. Based on procedure type, the spectrum ranges from minimally invasive to open surgery modalities; minimally invasive options are further distinguished by fluoroscopy-guided workflows and navigation-assisted platforms, while open surgery pathways frequently rely on manual technique and established exposure strategies.

End user segmentation underscores the operational trade-offs among ambulatory surgical centers, hospitals, and specialty clinics, as each setting dictates different throughput, sterilization, and inventory constraints that affect product selection. Approach differentiation across lateral, posterior, and posterior lateral corridors drives implant geometry and instrumentation pathways to address unique anatomic vectors and access limitations. Fixation mechanism segmentation spotlights interbody devices, plate fixation, rod fixation, and screw fixation alternatives, which are chosen based on desired stability, fusion strategy, and surgeon comfort. Finally, distribution channel segmentation between direct and distributor routes shapes commercial engagement models, post-market support expectations, and product availability in diverse geographies. Synthesizing these segmentation axes provides a structured framework for prioritizing product development, clinical evidence generation, and go-to-market tactics tailored to distinct stakeholder needs.

Regional dynamics and patient demographics influencing adoption rates reimbursement pathways clinical infrastructure and commercialization strategies across global regions

Regional dynamics materially influence adoption choices, regulatory priorities, and commercialization pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established clinical pathways and a high concentration of advanced spine centers support rapid diffusion of minimally invasive techniques and advanced implants, while the structure of hospital networks and ambulatory surgical center growth shapes procurement cycles and purchasing negotiations. Moving to Europe, the Middle East & Africa corridor, heterogeneous regulatory frameworks and reimbursement systems create diverse adoption timelines; some markets favor centralized procurement and cost-effectiveness analyses, whereas others prioritize rapid access to novel devices through private hospital systems.

In the Asia-Pacific region, a combination of large patient volumes, expanding surgical capacity, and increasing local manufacturing capability fosters both demand and competitive pricing pressure. Across these regions, differences in imaging infrastructure, surgeon training models, and facility throughput drive preference for specific approaches and fixation mechanisms. Furthermore, cross-regional partnerships, regulatory harmonization efforts, and strategic manufacturing investments are shifting how companies deploy distribution channels and support clinical training, thereby shaping long-term commercial viability in each geography.

Competitive landscape insights highlighting strategic moves product innovation partnerships go-to-market approaches and capability gaps among device manufacturers and service providers

Company strategies in the sacroiliac fusion space have coalesced around three principal themes: differentiated clinical value, integrated service offerings, and operational scalability. Competitors that emphasize robust clinical evidence and clear procedural advantages have focused R&D on implant design optimization and instrumentation ergonomics to shorten operative time and reduce complication profiles. Others have pursued integrated systems that bundle navigation, implants, and service agreements to lower the barrier for adoption among surgical teams and facilities. Strategic partnerships between device developers and imaging or navigation technology providers have emerged as an effective route to create cohesive offerings that address a full procedural workflow rather than single-point products.

Commercially, some firms prioritize direct account management for large health systems to capture long-term formularies and clinical integration opportunities, while alternative players leverage distributor networks to reach a wider set of hospitals and specialty clinics. Post-market surveillance, registry participation, and real-world evidence collection are increasingly important differentiators, as payers and providers expect longitudinal outcomes data. Additionally, capability gaps remain in lifecycle support for devices-especially in training, instrument maintenance, and logistics-which opens opportunities for companies that can deliver comprehensive service models that reduce operational friction for customers.

Actionable strategic recommendations for industry leaders to strengthen portfolios optimize operations accelerate adoption and navigate policy and supply chain headwinds

Industry leaders should pursue a set of coordinated actions that balance clinical differentiation, supply chain resilience, and market access effectiveness. First, prioritize investment in high-quality comparative clinical evidence and registries that align with payer requirements and surgeon decision criteria, enabling clearer demonstrations of procedural benefit across patient cohorts. Simultaneously, optimize implant portfolios by focusing on modularity and cross-compatibility to reduce inventory complexity for hospitals and ambulatory centers while accelerating adoption of newer materials and fixation options.

From an operational perspective, develop flexible sourcing strategies that combine regional manufacturing, dual suppliers, and inventory optimization to mitigate tariff and transport volatility. Strengthen commercial models by offering tailored service bundles for large health systems through direct channels while leveraging distributor partnerships to maintain geographic coverage in smaller facilities. Invest in surgeon training programs and digital education platforms to shorten the learning curve for navigation-assisted and minimally invasive techniques, and align reimbursement teams early to shape coding and payment pathways. Finally, incorporate lifecycle service offerings-instrument maintenance, data analytics, and outcomes support-to deepen customer relationships and create recurring revenue streams that stabilize long-term growth.

Transparent research methodology outlining data sources interview frameworks analytical approaches validation protocols and limitations ensuring robust evidence synthesis

The research approach combined a structured synthesis of peer-reviewed clinical literature, regulatory documents, procedural guidance, and stakeholder interviews to produce a robust evidence base. Primary data collection included interviews with clinicians across diverse practice settings, supply chain and procurement leaders, and device commercialization experts to capture real-world operational considerations and adoption drivers. Secondary research incorporated device labeling, clinical trial registries, and technical white papers to validate clinical performance attributes and device characteristics.

Analytical steps involved cross-referencing clinical outcomes with procedural approaches and device attributes to identify alignment and gaps across segmentation axes. Qualitative insights were triangulated with supply chain and policy analyses to assess the practical implications of trade and procurement dynamics. Validation processes included follow-up conversations with selected respondents and external expert review to ensure interpretive coherence. Limitations of the methodology include variation in regional data availability and the evolving nature of device approvals and procedural reimbursement pathways; these were mitigated by emphasizing trends supported by multiple independent sources and explicit documentation of assumptions underlying segmentation analyses.

Concise conclusion synthesizing clinical, commercial, and policy implications and outlining priorities for stakeholders to translate insights into strategic action

In summary, sacroiliac joint fusion is at an inflection point where device innovation, procedural refinement, and supply chain dynamics are collectively reshaping clinical practice and commercial strategies. Clinically, advances in imaging and navigation coupled with material and fixation innovations are expanding the safe application of minimally invasive techniques while preserving options for open surgery where appropriate. Commercially, segmentation across product types, procedural modalities, facility settings, approaches, fixation mechanisms, and distribution channels requires nuanced go-to-market planning that aligns product design with the operational realities of hospitals, ambulatory surgical centers, and specialty clinics.

Policy and trade developments have underscored the need for resilient sourcing and adaptable procurement models. Companies that combine compelling clinical evidence, streamlined instrumentation, and comprehensive lifecycle services will be best positioned to capture long-term clinical adoption and institutional partnerships. For stakeholders across the ecosystem, the emphasis should be on translating evidence into practice through training, integrated workflows, and value-based conversations with payers and providers to ensure patient access and procedural sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sacroiliac Joint Fusion Market, by Product Type

  • 8.1. Implants
    • 8.1.1. PEEK Cage
    • 8.1.2. Titanium Cage
  • 8.2. Instruments

9. Sacroiliac Joint Fusion Market, by Procedure Type

  • 9.1. Minimally Invasive
    • 9.1.1. Fluoroscopy Guided
    • 9.1.2. Navigation Assisted
  • 9.2. Open Surgery

10. Sacroiliac Joint Fusion Market, by Approach

  • 10.1. Lateral
  • 10.2. Posterior
  • 10.3. Posterior Lateral

11. Sacroiliac Joint Fusion Market, by Fixation Mechanism

  • 11.1. Interbody Devices
  • 11.2. Plate Fixation
  • 11.3. Rod Fixation
  • 11.4. Screw Fixation

12. Sacroiliac Joint Fusion Market, by Distribution Channel

  • 12.1. Direct
  • 12.2. Distributor

13. Sacroiliac Joint Fusion Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Sacroiliac Joint Fusion Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sacroiliac Joint Fusion Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sacroiliac Joint Fusion Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Sacroiliac Joint Fusion Market

18. China Sacroiliac Joint Fusion Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Alphatec Spine, Inc.
  • 19.6. Aurora Spine Corporation
  • 19.7. Camber Spine Technologies, LLC
  • 19.8. Captiva Spine, Inc.
  • 19.9. CoreLink, LLC
  • 19.10. DePuy Synthes, Inc.
  • 19.11. Foundation Fusion Solutions, LLC
  • 19.12. Genesys Orthopedic Systems, LLC
  • 19.13. Globus Medical, Inc.
  • 19.14. Life Spine, Inc.
  • 19.15. Medtronic plc
  • 19.16. NuVasive, Inc.
  • 19.17. Orthofix Medical Inc.
  • 19.18. PainTEQ, LLC
  • 19.19. RTI Surgical, Inc.
  • 19.20. SeaSpine Holdings Corporation
  • 19.21. SI-BONE, Inc.
  • 19.22. SIGNUS Medizintechnik GmbH
  • 19.23. Stryker Corporation
  • 19.24. VGI Medical, LLC
  • 19.25. Xtant Medical Holdings, Inc.
  • 19.26. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SACROILIAC JOINT FUSION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SACROILIAC JOINT FUSION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PEEK CAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PEEK CAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PEEK CAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY TITANIUM CAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY TITANIUM CAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY TITANIUM CAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FLUOROSCOPY GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FLUOROSCOPY GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FLUOROSCOPY GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY NAVIGATION ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY NAVIGATION ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY NAVIGATION ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY LATERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY LATERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY LATERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR LATERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR LATERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR LATERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INTERBODY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INTERBODY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INTERBODY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PLATE FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PLATE FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PLATE FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY ROD FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY ROD FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY ROD FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SCREW FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SCREW FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SCREW FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 159. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 160. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 186. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 187. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 195. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 196. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)